Evidence map›Paper›PMID 26748754›Full record

ReviewCell stem cell2016

Engineering Stem Cell Organoids.

Xiaolei Yin, Benjamin E Mead, Helia Safaee, Robert Langer, Jeffrey M Karp, Oren Levy

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell stem cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 428 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
428citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

428 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. [Organoid-based strategies and challenges in tissue regeneration].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. A practical toolbox for modelling fibrosis in vitro.Nature biomedical engineering · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. A Colon Cancer Organoid-on-a-Chip Model for In Vitro Therapy Assessment.International journal of molecular sciences · 2026
    Article
  10. Recent advancements and limitations of intestinal organoids for clinical applications.Progress in biomedical engineering (Bristol, England) · 2026
    Review
  11. When to create embryos or organoids for research.Journal of medical ethics · 2026
    Article
  12. Organoid technology in cancer research.Molecular biomedicine · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

368 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaolei YinDivision of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Cambridge, MA 02115, USA; Harvard Medical School, Cambridge, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard - MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Benjamin E MeadDivision of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Cambridge, MA 02115, USA; Harvard Medical School, Cambridge, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard - MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Helia SafaeeDivision of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Cambridge, MA 02115, USA; Harvard Medical School, Cambridge, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard - MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.
Robert LangerHarvard - MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jeffrey M KarpDivision of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Cambridge, MA 02115, USA; Harvard Medical School, Cambridge, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard - MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. Electronic address: jeffkarp.bwh@gmail.com.
Oren LevyDivision of Biomedical Engineering, Department of Medicine, Center for Regenerative Therapeutics, Brigham and Women's Hospital, Cambridge, MA 02115, USA; Harvard Medical School, Cambridge, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard - MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. Electronic address: levyorn@gmail.com.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
PHOTOPOLYMERIZATION FOR NONINVASIVE CARTILAGE TISSUER01DE013023 · NIDCR · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 1998 to 2019
$6.8M
Engineered Induction of a Stem Cell Homing ResponseR01HL095722 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2018
$3.9M
NCI NIH HHS P30 CA014051NHLBI NIH HHS HL095722NHLBI NIH HHS R01 HL095722NIDCR NIH HHS DE013023NIDCR NIH HHS R01 DE013023
6 · The paper itself

Abstract

Organoid systems leverage the self-organizing properties of stem cells to create diverse multi-cellular tissue proxies. Most organoid models only represent single or partial components of a tissue, and it is often difficult to control the cell type, organization, and cell-cell/cell-matrix interactions within these systems. Herein, we discuss basic approaches to generate stem cell-based organoids, their advantages and limitations, and how bioengineering strategies can be used to steer the cell composition and their 3D organization within organoids to further enhance their utility in research and therapies.

Indexed as

Cell Culture TechniquesAnimalsBrainCell CommunicationHumansIntercellular Signaling Peptides and ProteinsIntestinal MucosaMicrofluidicsOrganogenesisOrganoidsRegenerationStem CellsTissue EngineeringIntercellular Signaling Peptides and Proteins

Identifiers

PMID26748754
PMCPMC4728053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.